Can we predict who will benefit from immunotherapy? new study aims to find out.
NCT ID NCT07147361
First seen Jun 02, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both past and future, to develop a scoring system. The goal is to help doctors choose the right treatment for the right patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Etiology and Carcinogenesis
Beijing, Beijing Municipality, 100021, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1 inhibitor (with or without chemotherapy)
What this could lead to
If successful, this could help doctors predict which patients with squamous cell carcinoma will benefit from PD-1 inhibitors, leading to more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial. The biomarkers identified may not prove useful in practice, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.